Vertex Pharmaceuticals Incorporated (0QZU.L)
USD 499.1
(-0.75%)
USD 499.1
(-0.75%)
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2023 | 4.77 Billion USD | 38.5% |
| 2022 | 3.48 Billion USD | -10.44% |
| 2021 | 3.89 Billion USD | 49.66% |
| 2020 | 2.59 Billion USD | 7.75% |
| 2019 | 2.41 Billion USD | 22.24% |
| 2018 | 1.97 Billion USD | 8.42% |
| 2017 | 1.82 Billion USD | 22.98% |
| 2016 | 1.48 Billion USD | 7.81% |
| 2015 | 1.37 Billion USD | 18.29% |
| 2014 | 1.16 Billion USD | -9.38% |
| 2013 | 1.28 Billion USD | 3.07% |
| 2012 | 1.24 Billion USD | 12.14% |
| 2011 | 1.1 Billion USD | 34.32% |
| 2010 | 825.21 Million USD | 21.36% |
| 2009 | 679.98 Million USD | 9.99% |
| 2008 | 618.2 Million USD | 3.42% |
| 2007 | 597.78 Million USD | 39.16% |
| 2006 | 429.57 Million USD | 46.85% |
| 2005 | 292.53 Million USD | 24.85% |
| 2004 | 234.3 Million USD | -1.85% |
| 2003 | 238.71 Million USD | -5.42% |
| 2002 | 252.4 Million USD | 28.77% |
| 2001 | 196.01 Million USD | 73.88% |
| 2000 | 112.72 Million USD | 7.77% |
| 1999 | 104.6 Million USD | 28.66% |
| 1998 | 81.3 Million USD | 22.07% |
| 1997 | 66.6 Million USD | 43.84% |
| 1996 | 46.3 Million USD | -11.47% |
| 1995 | 52.3 Million USD | 19.41% |
| 1994 | 43.8 Million USD | 43.14% |
| 1993 | 30.6 Million USD | 84.34% |
| 1992 | 16.6 Million USD | 56.6% |
| 1991 | 10.6 Million USD | 65.63% |
| 1990 | 6.4 Million USD | 0.0% |
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2024 Q3 | 1.26 Billion USD | -78.18% |
| 2024 Q2 | 5.78 Billion USD | 378.89% |
| 2024 Q1 | 1.2 Billion USD | 1.49% |
| 2023 Q1 | 983.7 Million USD | 2.31% |
| 2023 Q4 | 1.19 Billion USD | 10.91% |
| 2023 FY | 4.82 Billion USD | 38.5% |
| 2023 Q2 | 1.04 Billion USD | 6.57% |
| 2023 Q3 | 1.07 Billion USD | 2.43% |
| 2022 Q4 | 961.5 Million USD | 7.82% |
| 2022 Q1 | 818.3 Million USD | -13.82% |
| 2022 Q2 | 815.4 Million USD | -0.35% |
| 2022 FY | 3.48 Billion USD | -10.44% |
| 2022 Q3 | 891.8 Million USD | 9.37% |
| 2021 Q1 | 648.05 Million USD | -4.48% |
| 2021 Q2 | 1.6 Billion USD | 147.17% |
| 2021 Q4 | 949.5 Million USD | 37.22% |
| 2021 FY | 3.89 Billion USD | 49.66% |
| 2021 Q3 | 691.94 Million USD | -56.8% |
| 2020 Q1 | 630.78 Million USD | -6.59% |
| 2020 FY | 2.59 Billion USD | 7.75% |
| 2020 Q4 | 678.42 Million USD | 0.06% |
| 2020 Q3 | 678.04 Million USD | 10.66% |
| 2020 Q2 | 612.73 Million USD | -2.86% |
| 2019 FY | 2.41 Billion USD | 22.24% |
| 2019 Q1 | 486.53 Million USD | -17.69% |
| 2019 Q4 | 675.28 Million USD | -5.64% |
| 2019 Q3 | 715.62 Million USD | 33.61% |
| 2019 Q2 | 535.59 Million USD | 10.08% |
| 2018 Q2 | 474.83 Million USD | 7.83% |
| 2018 Q4 | 591.09 Million USD | 26.35% |
| 2018 FY | 1.97 Billion USD | 8.42% |
| 2018 Q1 | 440.36 Million USD | -0.25% |
| 2018 Q3 | 467.8 Million USD | -1.48% |
| 2017 Q3 | 575.65 Million USD | 38.15% |
| 2017 Q2 | 416.7 Million USD | 7.71% |
| 2017 Q1 | 386.88 Million USD | 7.96% |
| 2017 Q4 | 441.45 Million USD | -23.31% |
| 2017 FY | 1.82 Billion USD | 22.98% |
| 2016 Q2 | 382.66 Million USD | 5.98% |
| 2016 FY | 1.48 Billion USD | 7.81% |
| 2016 Q1 | 361.07 Million USD | -11.39% |
| 2016 Q3 | 381.42 Million USD | -0.32% |
| 2016 Q4 | 358.36 Million USD | -6.05% |
| 2015 Q4 | 407.48 Million USD | 17.75% |
| 2015 Q1 | 301.45 Million USD | 7.67% |
| 2015 Q2 | 318.25 Million USD | 5.57% |
| 2015 FY | 1.37 Billion USD | 18.29% |
| 2015 Q3 | 346.05 Million USD | 8.74% |
| 2014 Q3 | 266.16 Million USD | -11.93% |
| 2014 Q2 | 302.22 Million USD | -3.5% |
| 2014 Q4 | 279.99 Million USD | 5.19% |
| 2014 FY | 1.16 Billion USD | -9.38% |
| 2014 Q1 | 313.17 Million USD | -3.58% |
| 2013 Q3 | 316.37 Million USD | -3.83% |
| 2013 Q2 | 328.97 Million USD | 5.79% |
| 2013 Q1 | 310.97 Million USD | -3.89% |
| 2013 Q4 | 324.79 Million USD | 2.66% |
| 2013 FY | 1.28 Billion USD | 3.07% |
| 2012 Q4 | 323.56 Million USD | 8.63% |
| 2012 Q3 | 297.84 Million USD | -5.16% |
| 2012 Q2 | 314.05 Million USD | 2.13% |
| 2012 Q1 | 307.51 Million USD | -0.26% |
| 2012 FY | 1.24 Billion USD | 12.14% |
| 2011 FY | 1.1 Billion USD | 34.32% |
| 2011 Q1 | 230.13 Million USD | -0.53% |
| 2011 Q2 | 270.26 Million USD | 17.44% |
| 2011 Q3 | 299.7 Million USD | 10.89% |
| 2011 Q4 | 308.31 Million USD | 2.87% |
| 2010 Q4 | 231.36 Million USD | 5.51% |
| 2010 FY | 825.21 Million USD | 21.36% |
| 2010 Q1 | 178.56 Million USD | 6.41% |
| 2010 Q2 | 195.99 Million USD | 9.76% |
| 2010 Q3 | 219.28 Million USD | 11.88% |
| 2009 Q1 | 172.1 Million USD | 1.94% |
| 2009 Q4 | 167.8 Million USD | -0.53% |
| 2009 FY | 679.98 Million USD | 9.99% |
| 2009 Q2 | 171.85 Million USD | -0.14% |
| 2009 Q3 | 168.7 Million USD | -1.83% |
| 2008 FY | 618.2 Million USD | 3.42% |
| 2008 Q1 | 136.2 Million USD | -1.86% |
| 2008 Q3 | 157.15 Million USD | 0.73% |
| 2008 Q2 | 156.02 Million USD | 14.55% |
| 2008 Q4 | 168.81 Million USD | 7.42% |
| 2007 Q2 | 159.5 Million USD | 6.97% |
| 2007 Q1 | 149.11 Million USD | 19.31% |
| 2007 FY | 597.78 Million USD | 39.16% |
| 2007 Q3 | 150.36 Million USD | -5.73% |
| 2007 Q4 | 138.79 Million USD | -7.7% |
| 2006 FY | 429.57 Million USD | 46.85% |
| 2006 Q4 | 124.98 Million USD | 12.71% |
| 2006 Q3 | 110.88 Million USD | 4.99% |
| 2006 Q2 | 105.62 Million USD | 19.91% |
| 2006 Q1 | 88.08 Million USD | 8.78% |
| 2005 Q4 | 80.96 Million USD | 8.93% |
| 2005 Q2 | 70.17 Million USD | 4.64% |
| 2005 Q3 | 74.32 Million USD | 5.92% |
| 2005 FY | 292.53 Million USD | 24.85% |
| 2005 Q1 | 67.06 Million USD | 1.76% |
| 2004 Q3 | 59.39 Million USD | 3.09% |
| 2004 Q2 | 57.61 Million USD | 12.09% |
| 2004 Q1 | 51.39 Million USD | -58.18% |
| 2004 FY | 234.3 Million USD | -1.85% |
| 2004 Q4 | 65.9 Million USD | 10.97% |
| 2003 Q2 | 105.04 Million USD | 93890.18% |
| 2003 Q4 | 122.9 Million USD | 106.37% |
| 2003 Q3 | 59.55 Million USD | -43.3% |
| 2003 Q1 | -112 Thousand USD | -100.16% |
| 2003 FY | 238.71 Million USD | -5.42% |
| 2002 Q1 | 58.11 Million USD | 5.63% |
| 2002 FY | 252.4 Million USD | 28.77% |
| 2002 Q3 | 63.55 Million USD | 6.1% |
| 2002 Q4 | 70.84 Million USD | 11.48% |
| 2002 Q2 | 59.89 Million USD | 3.06% |
| 2001 Q2 | 37.97 Million USD | 12.96% |
| 2001 Q3 | 50.1 Million USD | 31.96% |
| 2001 Q1 | 33.61 Million USD | 25.7% |
| 2001 Q4 | 55.01 Million USD | 9.8% |
| 2001 FY | 196.01 Million USD | 73.88% |
| 2000 Q2 | 28.59 Million USD | 5.17% |
| 2000 FY | 112.72 Million USD | 7.77% |
| 2000 Q4 | 26.74 Million USD | -11.46% |
| 2000 Q3 | 30.2 Million USD | 5.64% |
| 2000 Q1 | 27.18 Million USD | -4.61% |
| 1999 Q2 | 25.9 Million USD | 1.17% |
| 1999 Q1 | 25.6 Million USD | 0.79% |
| 1999 FY | 104.6 Million USD | 28.66% |
| 1999 Q3 | 24.5 Million USD | -5.41% |
| 1999 Q4 | 28.5 Million USD | 16.33% |
| 1998 Q4 | 25.4 Million USD | 17.59% |
| 1998 FY | 81.3 Million USD | 22.07% |
| 1998 Q1 | 16.4 Million USD | -12.3% |
| 1998 Q2 | 17.9 Million USD | 9.15% |
| 1998 Q3 | 21.6 Million USD | 20.67% |
| 1997 Q1 | 13.3 Million USD | 20.91% |
| 1997 Q2 | 14.2 Million USD | 6.77% |
| 1997 Q4 | 18.7 Million USD | -7.43% |
| 1997 Q3 | 20.2 Million USD | 42.25% |
| 1997 FY | 66.6 Million USD | 43.84% |
| 1996 Q2 | 12.3 Million USD | 3.36% |
| 1996 Q4 | 11 Million USD | -0.9% |
| 1996 FY | 46.3 Million USD | -11.47% |
| 1996 Q3 | 11.1 Million USD | -9.76% |
| 1996 Q1 | 11.9 Million USD | 3.48% |
| 1995 Q1 | 12 Million USD | -0.83% |
| 1995 FY | 52.3 Million USD | 19.41% |
| 1995 Q3 | 11.3 Million USD | -35.43% |
| 1995 Q4 | 11.5 Million USD | 1.77% |
| 1995 Q2 | 17.5 Million USD | 45.83% |
| 1994 FY | 43.8 Million USD | 43.14% |
| 1994 Q1 | 9.7 Million USD | -7.62% |
| 1994 Q2 | 11.1 Million USD | 14.43% |
| 1994 Q4 | 12.1 Million USD | 9.01% |
| 1994 Q3 | 11.1 Million USD | 0.0% |
| 1993 FY | 30.6 Million USD | 84.34% |
| 1993 Q1 | 5.2 Million USD | 13.04% |
| 1993 Q2 | 6.5 Million USD | 25.0% |
| 1993 Q4 | 10.5 Million USD | 28.05% |
| 1993 Q3 | 8.2 Million USD | 26.15% |
| 1992 Q2 | 1.3 Million USD | -63.89% |
| 1992 Q1 | 3.6 Million USD | 20.0% |
| 1992 FY | 16.6 Million USD | 56.6% |
| 1992 Q3 | 4.3 Million USD | 230.77% |
| 1992 Q4 | 4.6 Million USD | 6.98% |
| 1991 Q1 | - USD | 100.0% |
| 1991 Q4 | 3 Million USD | 15.38% |
| 1991 FY | 10.6 Million USD | 65.63% |
| 1991 Q3 | 2.6 Million USD | 0.0% |
| 1991 Q2 | 2.6 Million USD | 0.0% |
| 1990 Q1 | - USD | 0.0% |
| 1990 Q2 | - USD | 0.0% |
| 1990 Q4 | -6.4 Million USD | 0.0% |
| 1990 Q3 | - USD | 0.0% |
| 1990 FY | 6.4 Million USD | 0.0% |
| Name | Operating Expenses | Operating Expenses Difference |
|---|---|---|
| uniQure N.V. | 285.08 Million USD | -1574.933% |
| Abeona Therapeutics Inc. | 48.5 Million USD | -9744.955% |
| Aclaris Therapeutics, Inc. | 12.14 Million USD | -39229.545% |
| Agios Pharmaceuticals, Inc. | 408.8 Million USD | -1068.036% |
| Atara Biotherapeutics, Inc. | 275.69 Million USD | -1631.999% |
| Cara Therapeutics, Inc. | 142.46 Million USD | -3251.747% |
| Imunon, Inc. | 21.03 Million USD | -22605.194% |
| Dynavax Technologies Corporation | 219.14 Million USD | -2078.923% |
| Editas Medicine, Inc. | 247.3 Million USD | -1830.822% |
| FibroGen, Inc. | 398.11 Million USD | -1099.408% |
| Iovance Biotherapeutics, Inc. | 450.99 Million USD | -958.775% |
| Kala Pharmaceuticals, Inc. | 39.15 Million USD | -12095.745% |
| Neurocrine Biosciences, Inc. | 1.59 Billion USD | -199.092% |
| Sarepta Therapeutics, Inc. | 1.36 Billion USD | -250.892% |
| Supernus Pharmaceuticals, Inc. | 529.01 Million USD | -802.628% |
| Verastem, Inc. | 92.08 Million USD | -5085.483% |
| Zoetis Inc. | 2.76 Billion USD | -72.694% |
| Sangamo Therapeutics, Inc. | 228.68 Million USD | -1988.071% |
| Homology Medicines, Inc. | 9.87 Million USD | -48254.43% |
| Nektar Therapeutics | 190.9 Million USD | -2401.27% |
| Viking Therapeutics, Inc. | 100.82 Million USD | -4635.835% |
| Unity Biotechnology, Inc. | 44.66 Million USD | -10590.219% |
| Perrigo Company plc | 1.52 Billion USD | -212.398% |
| Esperion Therapeutics, Inc. | 271.89 Million USD | -1656.18% |
| Walgreens Boots Alliance, Inc. | 40.6 Billion USD | 88.239% |
| Illumina, Inc. | 3.81 Billion USD | -25.229% |
| Thermo Fisher Scientific Inc. | 10.25 Billion USD | 53.433% |
| IQVIA Holdings Inc. | 2.05 Billion USD | -132.586% |
| Heron Therapeutics, Inc. | 120.65 Million USD | -3857.499% |
| Waters Corporation | 943.51 Million USD | -406.085% |
| Biogen Inc. | 5.2 Billion USD | 8.26% |
| Evolus, Inc. | 189.75 Million USD | -2416.35% |
| Adicet Bio, Inc. | 152.03 Million USD | -3040.662% |
| bluebird bio, Inc. | 240.23 Million USD | -1887.662% |
| Geron Corporation | 70.44 Million USD | -6678.723% |
| Alnylam Pharmaceuticals, Inc. | 1.8 Billion USD | -165.269% |
| Amicus Therapeutics, Inc. | 427.65 Million USD | -1016.565% |
| Myriad Genetics, Inc. | 600.1 Million USD | -695.701% |
| Intellia Therapeutics, Inc. | 551.56 Million USD | -765.717% |
| Mettler-Toledo International Inc. | 1.08 Billion USD | -338.319% |
| Corbus Pharmaceuticals Holdings, Inc. | 13.9 Million USD | -34228.708% |
| BioMarin Pharmaceutical Inc. | 1.74 Billion USD | -173.439% |
| Regeneron Pharmaceuticals, Inc. | 2.81 Billion USD | -69.609% |
| Agilent Technologies, Inc. | 2.11 Billion USD | -125.768% |
| OPKO Health, Inc. | 574.68 Million USD | -730.889% |
| Exelixis, Inc. | 1.58 Billion USD | -200.925% |
| Corcept Therapeutics Incorporated | 368.61 Million USD | -1195.4% |
| Anavex Life Sciences Corp. | 55.75 Million USD | -8464.101% |
| Axsome Therapeutics, Inc. | 476.36 Million USD | -902.393% |
| Ionis Pharmaceuticals, Inc. | 779.58 Million USD | -512.504% |
| Halozyme Therapeutics, Inc. | 299.31 Million USD | -1495.293% |
| Blueprint Medicines Corporation | 722.86 Million USD | -560.57% |
| Insmed Incorporated | 949.26 Million USD | -403.023% |
| TG Therapeutics, Inc. | 198.47 Million USD | -2305.845% |
| Incyte Corporation | 1.19 Billion USD | -301.094% |
| Emergent BioSolutions Inc. | 1.04 Billion USD | -357.375% |